Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
29.1 ^USD	-0.21%		+0.48%	+0.55%

05-08	Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	MT
05-08	Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024

Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 08, 2024 at 09:05 pm

Supernus Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported revenue was USD 143.64 million compared to USD 153.76 million a year ago. Net income was USD 0.124 million compared to USD 16.95 million a year ago.

Latest news about Supernus Pharmaceuticals, Inc.

Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q1 Revenue $143.6M, vs. Street Est of $145.8M	05-08	MT
Transcript : Supernus Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024	05-08	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America	05-07	MT
M8 Pharmaceuticals, an Acino Company, Signs an Exclusive Licensing Agreement with Supernus for Qelbree® (Viloxazine Xr) in Latin America	05-07	CI
Supernus Pharmaceuticals, Inc. Announces Retirement of John M. Siebert from the Board of Directors	04-24	CI
Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	04-08	DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	04-08	MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	04-08	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	04-08	RE
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	03-25	MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	03-21	MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM	03-13
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating	02-28	MT
Transcript : Supernus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024	02-27
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	02-27	CI
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	02-27	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-27	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	02-27	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-27	CI
Supernus Pharmaceuticals, Inc. Announces Executive Changes	02-21	CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	02-05	MT
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada	12-19	MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada	12-19	MT

Chart Supernus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Sector

Pharmaceuticals

Calendar

23/05/2024 - R&D Day

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.1 USD

Average target price

40.67 USD

Spread / Average Target

+39.75%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SUPERNUS PHARMACEUTICALS, INC.	+0.55%	1.6B
KYOWA KIRIN CO. LTD.	+11.10%	8.96B
SK BIOPHARMACEUTICALS CO., LTD.	-10.76%	5.19B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+51.58%	4.77B
YUHAN CORPORATION	+12.50%	4.26B
BETTA PHARMACEUTICALS CO., LTD.	-20.70%	2.37B
INDIVIOR PLC	+12.83%	2.3B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.65%	2.21B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+19.51%	2.17B
VELOXIS PHARMACEUTICALS A/S	-0.50%	1.64B

Specialty & Advanced Pharmaceuticals